Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus NORQUEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus NORQUEST FE.
ENSKYCE vs NORQUEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Category C
Category C
Oral Contraceptive
Oral Contraceptive